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Background: Medulloblastoma is the most common malignant brain tumor of childhood. Although the clinical
outcome for medulloblastoma patients has improved significantly, children afflicted with the disease frequently
suffer from debilitating side effects related to the aggressive nature of currently available therapy. Alternative means
for treating medulloblastoma are desperately needed. We have previously shown that oncolytic measles virus (MV)
can selectively target and destroy medulloblastoma tumor cells in localized and disseminated models of the
disease. MV-NIS, an oncolytic measles virus that encodes the human thyroidal sodium iodide symporter (NIS), has
the potential to deliver targeted radiotherapy to the tumor site and promote a localized bystander effect above
and beyond that achieved by MV alone.
Methods: We evaluated the efficacy of MV-NIS against medulloblastoma cells in vitro and examined their ability to
incorporate radioiodine at various timepoints, finding peak uptake at 48 hours post infection. The effects of MV-NIS
were also evaluated in mouse xenograft models of localized and disseminated medulloblastoma. Athymic nude
mice were injected with D283med-Luc medulloblastoma cells in the caudate putamen (localized disease) or right
lateral ventricle (disseminated disease) and subsequently treated with MV-NIS. Subsets of these mice were given a
dose of 131I at 24, 48 or 72 hours later.
Results: MV-NIS treatment, both by itself and in combination with 131I, elicited tumor stabilization and regression in
the treated mice and significantly extended their survival times. Mice given 131I were found to concentrate
radioiodine at the site of their tumor implantations. In addition, mice with localized tumors that were given 131I
either 24 or 48 hours after MV-NIS treatment exhibited a significant survival advantage over mice given MV-NIS
alone.
Conclusions: These data suggest MV-NIS plus radioiodine may be a potentially useful therapy for the treatment of
medulloblastoma.
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Medulloblastoma is the most common malignant brain
tumor of childhood [1]. Our understanding of this dis-
ease, its etiology, and treatment has improved consider-
ably over the past several years and is reflected in 5-year
survival rates that now exceed 70% [2]. Despite these
advancements, numerous challenges in the effective
treatment of medulloblastoma remain. Conventional
therapy, consisting of surgical resection and craniospinal
irradiation with or without chemotherapy, is frequently
associated with neurocognitive morbidity. Patients trea-
ted for medulloblastoma often display impaired
intelligence and deficits in processing speed, memory
ability, and attention, which significantly impact their
quality of life [3,4]. In addition, a sizable subset of
medulloblastoma patients will effectively remain incur-
able, owing to medulloblastoma’s propensity to dissem-
inate in cerebrospinal fluid (CSF) spaces, including the
ventricles, intracranial subarachnoid space, and spinal
subarachnoid space [5,6]. Fewer than 20% of children
who present with disseminated medulloblastoma will
survive more than five years [7]. Alternative treatment
modalities for medulloblastoma are clearly needed.
One promising approach is the development and use
of oncolytic measles viruses (MV). As derivatives of the
Edmonston vaccine strain, these viruses display a natural
tropism for the CD46 membrane protein, an inhibitory
complement regulator strongly over-expressed by many
types of tumor relative to normal tissue [8,9]. MV pre-
ferentially infects tumor cells and induces their death via
syncytia formation and apoptosis, causing minimal dam-
age to the normal surrounding tissue [10,11]. In a re-
cently published study, we reported that the majority of
medulloblastomas over-express CD46 and were conse-
quently susceptible to MV oncolysis [12]. We also
demonstrated that MV virotherapy was effective against
orthotopic mouse xenograft models of localized and dis-
seminated medulloblastoma [12,13]. In these studies,
multiple intratumoral injections of MV were found to
significantly reduce tumor burden and extend survival
in treated animals. Further studies aimed at scaling back
the number of intratumoral MV injections revealed a
marked decrease in the efficacy of the treatment (un-
published data), prompting us to explore the use of
genetically modified MV that offer enhanced killing of
tumor cells.
The insertion of specific transgenes into the MV gen-
ome can be used to confer increased specificity, augment
MV killing of infected tumor cells, or provide markers
to assess virus delivery and tumor response [9]. MV-
NIS, an oncolytic MV engineered to express the human
thyroidal sodium iodide symporter (NIS), was developed
to provide a noninvasive means of imaging tumors and
to potentially enhance the efficacy of MV againstradiosensitive malignancies by concentrating radioiodine
in virus-infected cells [14]. MV-NIS was shown to ex-
hibit a profound synergy with the β- particle emitting
radioiodine isotope 131I in a multiple myeloma xenograft
model, wherein the administration of 37 MBq 131I at
peak infection resulted in complete tumor regression in
all the animals under study [14]. More recently, the
combination of MV-NIS and 131I was found to have sig-
nificant antitumor activity against an orthotopic model
of glioblastoma multiforme, an invasive and radiosensi-
tive primary brain tumor [15]. Because medulloblasto-
mas are also known to be extremely radiosensitive [2],
we hypothesized that MV-NIS virotherapy in combin-
ation with 131I could promote enhanced tumor regres-




The Vero, D283med and UW426 cell lines were
obtained from the American Type Culture Collection.
The D283med-Luc cell line was generated as described
previously [12]. These cell lines were maintained in
DMEM supplemented with 10-20% FBS, 1% penicillin/
streptomycin and 2mM L-glutamine and cultured at
37°C in a humidified incubator set at 5% CO2. The
FRTL-5 cell line was the kind gift of Dr. Lawrence
Kirschner of the Ohio State University and was cultured
as described elsewhere [16].
MV-NIS production and titration
The MV-NIS virus was the kind gift of Stephen J. Russell
at the Mayo Clinic in Rochester, Minnesota. MV-NIS
stocks were propagated by infecting Vero cells at an
MOI of 0.01 in a minimal volume of OptiMEM (Invitro-
gen, Carlsbad, CA) for 2 hours. Unbound virus was then
removed and replaced with DMEM with 10% FBS and
the cells were incubated an additional 48–72 hours at
37°C. When the majority of the Vero cells had fused into
syncytia, the media was removed and the cells were
scraped into a small volume of OptiMEM. MV-NIS was
harvested by two cycles of freezing in liquid nitrogen
and thawing, followed by centrifugation at 10,000xG to
pellet and remove cellular debris. Aliquoted virus was
stored at −80°C. Viral titers were determined by 50% tis-
sue culture infective dose (TCID50) titration on Vero
cells [17].
In vitro infection assays
D283med and UW426 cells were seeded in six-well
plates at a density of 2.5 × 105 cells/well. After 24 hours
of incubation, when the cells had reached approximately
70-80% confluency, they were infected with MV-NIS or
MV-GFP at MOIs of 0.01, 0.1 and 1 in 200μl of
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replaced with 3 ml of DMEM. Cells were monitored
under a microscope for the appearance of syncytia over
the next 72 hours and photographed with a Spot RT KE/
SE digital camera (Diagnostic Instruments Inc., Sterling
Heights, MI). In vitro kill curves were constructed by de-
termining the number of viable cells at each time point
and MOI by trypan blue exclusion. The percentage of
surviving cells was calculated by dividing the number of
viable cells in an infected well by the number of viable
cells in the uninfected well corresponding to the same
time point. Sample and control wells were seeded and
counted in triplicate.
In vitro MV-NIS-mediated 125I uptake and retention assays
UW426 and D283med cells were seeded in 6-well plates
at a density of 1.5 × 105 cells/well and 5 × 105 cells/well
respectively. The cells were infected 24 hours later with
MOI 0.1 MV-NIS or MV-GFP in 250 μl OptiMEM and
allowed to incubate for an additional 2 hours. Following
infection, the media was aspirated and replaced with
DMEM until the time of the uptake assay. At each time
point, the cells were washed once with warm Hanks’
Balanced Salt Solution (HBSS) and then placed in 900 μl
HBSS+10mM HEPES, with or without 100 μM KClO4.
One-hundred μl of 125I (1 × 105 cpm total) was then
added and the cells were incubated for 45 minutes at
37°C. The plates were then washed with cold HBSS
+10mM HEPES, aspirated, and 1 ml of 1M NaOH was
added to each well. After shaking for 15 minutes, the
NaOH solution was removed and its radioactivity was
quantified with a Cobra II gamma counter. Samples were
set up and quantified in triplicate. Data is presented as
counts per minute per 104 cells.
Radioiodine retention was measured using a slight
modification of the above protocol. Following the 45 mi-
nute exposure of 125I, the media covering the cells was
collected and replaced with fresh HBSS+10mM HEPES
every 3 minutes for a total of 30 minutes. Cells were
then lysed and collected in 1M NaOH at the last time-
point. Total radioactivity at the beginning of efflux was
calculated by adding the cpm of each supernatant to that
of the lysed cells. Each sample was run in quadruplicate.
In vivo xenograft studies
Localized and disseminated models of medulloblastoma
were constructed as described previously [12,13]. In
brief, 1x106 D283med-Luc cells suspended in 7 μl PBS
were implanted into the caudate nucleus (localized
model) or right lateral ventricle (disseminated model) of
5-week-old Hsd:Athymic Nude-Foxn1nu mice (Harlan
Laboratories, Indianapolis, IN). Bioluminescent imaging
was conducted prior to initiating treatment in order to
ensure that tumor burdens were roughly equivalent.Treatment with MV-NIS (2 × 105 pfu/dose) or an
equivalent volume of an OptiMEM vehicle control was
initiated seven days post tumor implantation for the
localized medulloblastoma mice or three days for the
disseminated model mice. The mice placed into 131I
treatment groups were switched to low-iodine diets and
given daily IP injections of 5μg L-thyroxine one week
prior to the administration of 131I. A single 37 MBq dose
of 131I (Cardinal Radiopharmacy, Columbus, OH) was
delivered by IP injection 24–72 hours post MV-NIS
treatment. The animals were observed over the following
weeks and euthanized if they became lethargic, displayed
cachexia or exhibited hemiparesis or other motor im-
pairment. All studies involving animals were approved
by the Institutional Animal Care and Use Committee at
The Research Institute at Nationwide Childrens’ Hos-
pital (protocol number: AR08-00019).
Bioluminescent imaging of tumor and 131I uptake
Bioluminescent imaging was conducted using the Xeno-
gen Ivis Spectrum (Caliper Life Sciences, Hopkinton,
MA). Animals were given an IP injection of 4.5 μg
Xenolight Rediject D-Luciferin (Caliper Life Sciences)
and kept under general anesthesia with isoflurane in O2
delivered by a veterinary vaporizer. Images were
obtained 20 minutes after luciferin administration. Up-
take of 131I was visualized as Cherenkov luminescence
on the same system [18]. Imaging of 131I uptake was per-
formed 24 hours after tumor bioluminescent images
were acquired to allow for complete clearance of the
luciferin. Image acquisition time was set for a 5 minute
exposure. Flux is displayed as average radiance
(photons/second/cm2/steradian).
Histopathological evaluation
At the time of necropsy, brains and decalcified spinal
columns were fixed overnight in 10% buffered formalin
phosphate. They were then paraffin embedded, cut into
4 μm tissue sections, and stained with hematoxylin and
eosin (H&E). Individual sections were visualized under a
Zeiss Axioskop 2 Plus microscope and photographed
with a Zeiss AxioCam MRc camera (Carl Zeiss MicroI-
maging, LLC., Thornwood, NY).
Immunohostochemistry
IHC of tissue slides with anti-Measles Nucleoprotein
antibody (NB100-1856; Novus Biologicals, Littleton, CO)
was carried out as described previously [13].
Statistical analysis
Survival curves were generated using the Kaplan-Meier
method and GraphPad Prism version 5.01 software
(GraphPad Software, Inc.).Comparisons of survival were
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statistically significant if p ≤ 0.05.
Results
MV-NIS infects medulloblastoma cells and promotes the
uptake of radioiodine
We initially tested the efficacy of the MV-NIS virus
in vitro against two established medulloblastoma cell
lines, UW426 and D283med (Figure 1). These cell lines
were previously shown to express abundant levels of the
measles virus receptor CD46 and were susceptible to in-
fection with an attenuated Edmonston-strain MV [12].
The addition of the NIS gene had no impact on measles
virus’ cytotoxic activity, and syncytia formation was read-
ily observed in both UW426 and D283med infected at
MOIs as low as 0.01 within 48 hours (Figure 1A). In
vitro kill curves showed that MV-NIS was just as effect-
ive or better at killing these medulloblastoma cell lines
than a control MV encoding green fluorescent protein
(MV-GFP), resulting in greater than 90% cell death
within 72 hours of infection (Figure 1B-C). We con-
firmed the expression of functional NIS by performing
radioiodide 125I uptake assays in UW426 and D283med
following 24, 48 or 72 hours of infection with MV-NIS
or MV-GFP. Increased uptake of 125I was observed only in
the cells infected with MV-NIS, peaking at 48 hours post
infection (Figure 2A-B). Extensive cell-death preventedFigure 1 MV-NIS induces syncytia formation and cell death in medull
lines were infected with MV-NIS at MOIs of 0.01, 0.1 and 1 and then mon
days. The photographs shown here were taken at 100X magnification aft
D283med infected with MV-NIS or MV-GFP. Viability was determined by t
number of viable cells were averaged and expressed as a percentage of
represent one standard deviation.measurement of 125I uptake after 72 hours of infection.
The addition of KClO4, a competitive substrate for NIS,
resulted in the near complete elimination of 125I uptake.
The failure of MV-GFP infected cells to incorporate 125I
demonstrates that NIS expression is responsible for the
observed increases in 125I uptake. We then performed
radioiodide retention studies in order to gauge how long
the MV-NIS infected cells were retaining 125I. For these
experiments, we infected UW426 and D283med with
MV-NIS (MOI 0.1) for 48 hours and incubated them in
the presence of 125I. The media covering these cells was
then collected and replaced at 3 minute intervals, and
the radioactivity in each sample was measured at the
experiment endpoint. A rat thyroid cell line, FRTL-5,
was similarly assayed for the purpose of comparison. We
found the efflux of 125I to be rapid and comparable for
each medulloblastoma cell line, displaying a 125I t1/2
retention time of approximately 1.5 minutes. In contrast,
the t1/2 retention time in FRTL-5 was approximately
13.5 minutes (Figure 2C).
In order to determine whether MV-NIS infection
could also promote radioiodine uptake in our in vivo
model of localized medulloblastoma, we treated mice
bearing D283med-Luc tumors with MV-NIS (2 × 105
TCID50) and gave them a single IP injection of
131I (37
MBq) 48 hours later. The mice were imaged the follow-
ing day with a Xenogen Ivis Spectrum imaging system.oblastoma cell lines. A. UW426 and D283med medulloblastoma cell
itored for the appearance of syncytia formation over the next three
er 48 hours of infection. B-C. In vitro kill curves for UW426 and
rypan blue exclusion, and each sample was run in triplicate. The
an uninfected control for each corresponding timepoint. Error bars
Figure 2 MV-NIS promotes radioiodine uptake in infected medulloblastoma cells. Radionuclide uptake assays were performed with A.
UW426 and B. D283med. Each cell line was infected with MV-NIS or MV-GFP (MOI of 0.1) and then exposed to 1 × 105 cpm of 125I at 24, 48 or 72
hours post infection. Due to excessive cell death at 72 hours, only data from the 24 and 48 hour timepoints are shown. The addition of KClO4 to
the cells effectively blocked incorporation of 125I. Each sample was run in triplicate, with error bars representing one standard deviation. +/−
denotes the presence or absence of KClO4 respectively. C. Radioiodine kinetics in UW426 and D283med 48 hours after MV-NIS infection. Efflux of
125I is rapid, with a t1/2 retention time of approximately 1.5 minutes for each cell line. Data points are the average of four independent samples.
D. Medulloblastoma xenografts incorporate 131I following MV-NIS infection. The mouse in the left panels received a 2 × 105 TCID50 intratumoral
injection of MV-NIS three days following tumor implantation whereas the mouse in the right panels was given an equal volume of OptiMEM to
serve as a vehicle control. Tumor bioluminescence was visualized 48 hours later, and the mice were subsequently given an IP injection of 37 MBq
131I. Cherenkov luminescence from the irradiated tumors was then visualized the following day.
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ation as it decays, producing visible light that can be
detected with ultra-sensitive charge-coupled device cam-
eras [19,20]. Figure 2D shows representative biolumines-
cent images of an MV-NIS treated mouse side by side
with a vehicle control. The MV-NIS mouse shows an
increased bioluminescent signal originating from the
tumor where 131I has accumulated. Strong biolumines-
cent signals were also noted in the stomach and bladder
regions of some of the mice (data not shown).
We conducted similar studies with mice implanted
with D283med-Luc in their lateral ventricles. In this par-
ticular model, the tumor disseminates within the CSF
into the cranial and spinal subarachnoid spaces and
closely recapitulates human disseminated medulloblas-
toma [13]. Despite repeated efforts, we were unable to
detect 131I accumulation in the spinal tumors of these
mice (data not shown).MV-NIS treatment with and without 131I prolongs
survival in mouse xenografts
We next sought to determine whether MV-NIS virother-
apy in combination with 131I conferred any survival ad-
vantage over MV-NIS alone in mice bearing intracranial
medulloblastoma tumors. A total of 48 mice were
implanted with D283med-luc cells in their caudate nu-
clei, and the tumors were given seven days to establish
prior to treatment. During this time, the animals were
switched to a low-iodine diet and given daily IP injec-
tions of L-thyroxine in order to suppress their thyroidal
expression of NIS [21]. We imaged the tumors 7 days
following implantation and observed that the animals
had comparable tumor burdens on the basis of total
emitted flux, however 4 mice had developed spinal me-
tastases and were excluded from further study. The
remaining mice were randomly assigned into the follow-
ing groups: MV-NIS only (5 mice); MV-NIS + 131I at 24
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MV-NIS + 131I at 72 hours (6 mice); 131I only (5 mice);
and vehicle control (8 mice). Mice in the treated groups
were given a single intratumoral injection of MV-NIS
(2 x 105 TCID50), followed by an IP injection of
131I at
the appropriate timepoint. A schematic of the experi-
mental design is shown in Figure 3A. All MV-NIS treated
groups exhibited significant increases in survival time
compared to the vehicle and 131I controls (p < 0.0001)
(Figure 3B). Mice that received 131I at 24 or 48 hours
after MV-NIS treatment, however, displayed statistically
significant prolongation of survival compared to those
given MV-NIS alone (p = 0.01 and 0.009 respectively).
One of the mice in the 24 hour group and one in the
48 hour group survived symptom-free until the experi-
ment endpoint at 100 days post tumor implantation. In
contrast, the mice given 131I after 72 hours exhibited
similar survival times to those given MV-NIS alone
(p = 0.3). The administration of 131I by itself without
prior MV-NIS treatment was found to produce no sur-
vival benefit over the vehicle controls (p = 0.3).
A similar series of survival studies was conducted in
35 mice with disseminated D283med-luc tumors
(Figure 3C). In contrast to the localized medulloblas-
toma model, the mice in this set of experiments were
treated 3 days after tumor implantation as opposed to 7
days. This discrepancy in timing was necessary as rapid
occlusion of the ventricles by growing tumor cells can
prevent efficient spread of the virus to distant sites [13].
Twenty mice were treated with MV-NIS, and 10 of these
animals were subsequently given an IP injection of 131I
48 hours afterwards. The remaining 15 mice served asFigure 3 MV-NIS treatment with and without 131I prolongs survival in
localized medulloblastoma MV-NIS + 131I survival study. B. Kaplan-Meier sur
with 2 × 105 TCID50 MV-NIS seven days post tumor implantation. The mice
48, or 72 hours following MV-NIS treatment. The 131I-only mice were given
controls were treated with OptiMEM. C. Survival analysis of mice with disse
tumor implantation.vehicle and 131I controls (n of 10 and 5, respectively).
MV-NIS treatment had a significant impact on overall
survival (p < 0.0001) and nearly doubled median survival
times from 39 days for the control animals to 74.5 days
and 80 days for the MV-NIS and MV-NIS + 131I animals
respectively. The addition of 131I to MV-NIS only pro-
duced a trend towards increased survival over the virus
alone however, and did not quite reach statistical sig-
nificance (p = 0.06). Two mice from the MV-NIS +
131I group survived symptom-free until the experiment
endpoint at 100 days post tumor implantation, whereas
the entirety of the MV-NIS only group succumbed
within 84 days.
Histology of MV-NIS treated tumors
Distribution of MV-NIS in the treated tumors was evalu-
ated by immunohistochemistry (IHC) using an antibody
specific for the MV nucleoprotein. Mice bearing
D283med-luc intracranial tumors were treated once with
MV-NIS (2 × 105 TCID50) and then sacrificed for ana-
lysis at days 7, 14 and 21 post treatment (Figure 4A-C
respectively). Increasing numbers of syncytia and MV-
NIS-positive tumor cells could be detected at each time-
point, concomitant with greater levels of tumor clearance.
When we performed histological examination of the
animals in the localized medulloblastoma model sur-
vival studies, we found substantial tumor masses in the
caudate nuclei of the control and 131I-only mice. Brains
from all groups of MV-NIS treated mice showed large
areas of tumor clearance surrounding the injection site,
but small foci of tumor that had escaped MV oncolysis
could be detected at distant sites of the cerebellum andmouse models of medulloblastoma. A. Experimental design of the
vival analysis of mice with localized medulloblastoma tumors treated
were subsequently given a 37 MBq dose of 131I by IP injection at 24,
radioiodine five days following tumor implantation. Mice denoted as
minated tumors. MV-NIS treatment was administered three days after
Figure 4 Histological examination of mice treated with MV-NIS. Representative IHC of a mouse brain after staining with an anti-MV
nucleoprotein antibody A. 7 days, B. 14 days and C. 21 days following intratumoral injection with 2 × 105 TCID50 MV-NIS. D. IHC of a tumor-free
mouse brain with the same antibody, showing sparse off-target infection of cortical neurons. E. H&E staining of a spinal cord section from a
control mouse in the disseminated medulloblastoma survival study showing extensive tumor infiltration. F. A spinal cord section from a mouse
treated with MV-NIS + 131I. No evidence of tumor could be found in the spinal canals of five of six total animals in this treatment group.
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visible symptoms until the experiment endpoint were
also found to be free of viable tumors (data not shown).
During the course of this examination, we noted that
several additional treated animals that had succumbed
prior to the experiment endpoint were also determined
to be tumor-free. These included two additional animals
in the MV-NIS with 131I at 24 hours group (three of 10
animals tumor-free), four animals from the MV-NIS +
131I at 48 hours group (five of 10 animals tumor-free),
and three animals from the MV-NIS + 131I at 72 hours
group (three of six animals tumor-free). Prior to death,
these animals had exhibited significant wasting, became
lethargic and had assumed a kyphotic posture. Because
these symptoms have been associated with MV-induced
encephalitis in immunocompromised mice [22], we per-
formed IHC on brain sections from these seemingly
cured animals to assess the extent of any residual MV
infection (Figure 4D). Although off-target infection of
cortical neurons was evident in some of these sections,
these events were generally rare and unaccompanied by
any overt indications of an inflammatory response that
would be indicative of encephalitis.
We also performed histological examination of the
brains and spinal cords from mice in the disseminated
medulloblastoma model survival studies. Tumor depos-
its could be found in the ventricles, cerebellum, brain-
stem, and cranial and spinal subarachnoid spaces of theOptiMEM control and 131I-only mice (Figure 4E). Com-
parable tumor masses were also found in the MV-NIS
treated groups, suggesting that pockets of the tumor had
managed to escape MV oncolysis or radiological cell kill-
ing. We could find no evidence of spinal metastases in
two of the six mice from the MV-NIS only group and
five of the six mice from the MV-NIS + 131I group how-
ever, despite the presence of these tumors being con-
firmed via bioluminescent imaging at the outset of the
experiment (Figure 4F).
Discussion
Although current treatment strategies for medulloblas-
toma are effective, they carry inherent risks and are
associated with significant morbidity [23-25]. Radiation
therapy, in particular, is known to produce a broad
spectrum of cognitive and endocrine impairments in
surviving patients [26,27]. With these issues in mind, the
focus of many labs has shifted towards identifying ther-
apies that are both effective against and highly specific
for transformed cells, hopefully mitigating the need for
more conventional therapy. In this study, we evaluated
the oncolytic activity of MV-NIS used in conjunction
with 131I against two xenograft models of medulloblas-
toma, seeking to combine measles virotherapy with tar-
geted radiotherapy. As a derivative of the attenuated
Edmonston vaccine strain, MV-NIS is able to efficiently
enter cells through the CD46 receptor and promote
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cessful infection and viral propagation is dependent
upon high expression of CD46 on the target cell mem-
brane, and this reliance on receptor abundance allows
MV-NIS to functionally discriminate between normal
and tumor cells [28,29]. The CD46 receptor is highly
expressed in medulloblastoma, making this cancer a
suitable target for MV virotherapy [12].
MV-NIS has shown impressive oncolytic activity in
multiple preclinical tumor models [14,28,30-32], and its
ability to promote iodide uptake in infected tumor cells
has made targeted radiotherapy feasible for cancers of
various origins. Targeted radiotherapy differs from con-
ventional external beam radiotherapy in that it delivers
low doses of radiation over prolonged periods of time
and tends to promote non-necrotic mechanisms of cell
death through localized, but potent, bystander effects
that minimize unintended damage to the normal sur-
rounding tissue [33]. Additional cell killing by radio-
logical cross-fire is also predicted to occur with
radionuclides like 131I, whose decay produces β- particles
that travel long distances (up to 0.36 mm) and introduce
single-strand DNA breaks in the cells they traverse be-
fore dissipating [34]. Since medulloblastomas are highly
susceptible to MV oncolysis and known to be radiosensi-
tive [2,35], we hypothesized that a targeted radiovir-
otherapy approach using MV-NIS with 131I would be
more effective than MV virotherapy alone.
We were able to confirm that a single intratumoral in-
jection of MV-NIS was capable of promoting 131I uptake
in the cranial tumors of treated mice using an emerging
imaging modality known as Cherenkov luminescent im-
aging (CLI). Cherenkov radiation is a phenomenon
where charged particles move faster than the speed of
light through the medium in which they travel, emitting
optical photons in the process [18]. These particles,
which are produced during the decay of β--emitting
radionuclides, can be subsequently detected by a sensi-
tive charge-coupled device camera like the Xenogen Ivis
Spectrum used in the experiments detailed above. Al-
though the utility of CLI as an imaging modality is cur-
rently limited to small-animal molecular imaging, it can
provide a means to semi-quantitatively determine signal
intensity and spatial distribution of radionuclides like
131I where conventional imaging modalities such as posi-
tron emission tomography (PET) or single-photon emis-
sion computed tomography (SPECT) are unavailable or
cost prohibitive [36].
Kaplan-Meier analysis of our localized medulloblas-
toma survival studies suggests that the animals did bene-
fit from the inclusion of 131I to their MV-NIS treatment,
provided that the 131I was administered within a 24–48
hour window after infection. These time points most
likely encompass the period of peak MV-NIS infectionin our medulloblastoma model, where infected tumor
cells have begun expressing NIS but have yet to fully
undergo lysis, and would correlate with our in vitro
observations (Figure 2A-B). The addition of 131I at 72
hours post infection, the last time point we evaluated,
had no impact on overall survival. These results are also
in agreement with similar observations reported by Pen-
heiter et al., who evaluated MV-NIS radiovirotherapy in
a mouse xenograft model of pancreatic cancer [32].
In our disseminated medulloblastoma survival studies,
the addition of 131I to MV-NIS treated animals produced
a moderate increase in survival over MV-NIS only trea-
ted animals that approached the threshold of statistical
significance (p = 0.06). Disseminated disease is an espe-
cially grave prognostic factor, and has proven to be ex-
ceptionally difficult to effectively treat [13]. Despite an
overt lack of synergy with 131I, MV-NIS was effective as
an oncolytic agent and extended the median survival
times of the treated animals to nearly double that of
their respective vehicle controls (Figure 3C). It is also
important to note that we were unable to find spinal
tumors in five of the six animals given MV-NIS + 131I at
time of autopsy, suggesting that these animals may have
died due to residual tumors around their brainstems and
cerebella. Future experiments aimed at optimizing virus
delivery and 131I dosing may eventually yield enhanced
efficacy in this model.
During the course of the localized medulloblastoma
survival studies, a substantial number of treated and
otherwise tumor-free mice succumbed prior to the ex-
periment endpoint. Although it is difficult to draw de-
finitive conclusions, there are two possible explanations
for these unexpected occurrences. One possibility is that
the mice developed an adverse reaction to the measles
virus on account of their severely immunocompromised
state. In mice, resistance and susceptibility to MV-induced
encephalitis is governed by their major histocompatibility
complex haplotype [37]. Nude mice, characterized by
their thymic aplasia, are unable to produce functional
CD4+ and CD8+ T lymphocytes, which play important
roles in clearing MV from the central nervous system [38].
Neurologic disease has been shown to occur in these ani-
mals following intracerebral inoculation with Edmonston
strain MV, albeit after long incubation periods (49 to
140 days after 104 pfu virus) [22]. For comparison, the
seemingly cured mice from our studies died between days
45 and 87 following MV-NIS treatment. We did observe
off-target MV infection in a small population of neurons
from the treated mice, but these were unaccompanied by
signs of inflammation, neuronal death, or any symptoms
of neurotoxicity in the animals prior to their sacrifice.
An alternative explanation may be that the animals
succumbed to the effects of gastrointestinal toxicity fol-
lowing 131I administration. Although NIS is predominately
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the gastric mucosa of mice [39]. Uptake of 131I by these
gastric cells will eventually lead to their death, culminating
in animal malnutrition over the long term [15,39]. Inci-
dentally, the mice in our studies that died free of tumor
all came from treatment groups that received an IP dose
of 131I, but we did not collect their gastric tissue for
further analysis at the time of this study. A recently
published paper by Opyrchal and colleagues examined
MV-NIS + 131I radiovirotherapy in glioma however, and
determined gastrointestinal toxicity to be the likely cause
of premature death in their animals under study [15].
Whether the cause of death in these animals was due
to the MV or the 131I itself, the toxicity observed here
should not extend to immunocompetent human beings.
The side effects for 131I-based therapies in humans are
generally mild when administered in reasonable doses
[40,41] and the safety of MV-NIS has been vetted in pre-
clinical toxicity studies and phase I clinical trials [42-44].
MV-NIS is a derivative of the Edmonston vaccine strain,
a highly attenuated strain of measles virus that has a re-
markable safety record spanning over a billion recipients
worldwide [45]. With close to five decades of use, its re-
version to pathogenicity has never been reported [46].
Extensive studies have also shown no clinical evidence
of toxicity in non-human primates following intracereb-
ral injection of Edmonston strain MV [47,48]. In
addition, phase I clinical trials with oncolytic MV are
presently underway for treatment of multiple myeloma
[44], recurrent glioblastoma multiforme [49], and ovar-
ian cancer [43]. While data from these trials is still forth-
coming, no dose-limiting toxicity has been observed
following delivery of MV up to 109 TCID50 by IP or IV
administration and up to 107 TCID50 for MV delivered
through the central nervous system [50]. We have re-
cently proposed a Phase 1 clinical trial investigating the
use of oncolytic MV to treat recurrent medulloblastoma.
While we foresee no complications with MV-associated
toxicity, additional measures to further restrict MV rep-
lication to tumor cells are available should they be
deemed necessary [51,52].
Conclusions
The data presented here show that MV-NIS virotherapy
is an effective means of treating medulloblastoma in
mouse xenografts, and that its oncolytic activity against
localized tumors can be further enhanced by the subse-
quent IP administration of 37 MBq of 131I at 24 or 48
hours of viral delivery. Proper timing of 131I administra-
tion treatment appears to be critical in this tumor
model, as this survival benefit was lost when 131I was
given 72 hours after MV-NIS treatment. Significant
questions remain to be addressed however. Despite its
utility in determining whether 131I has been concentratedby the tumor, CLI currently lacks the resolution to pro-
vide tomographic detail about and quantification of
radioactivity uptake. Understanding these parameters
will be necessary before extrapolating the potential of
MV-NIS-based therapies to human medulloblastoma
patients, as effective radionuclide therapy is dependent
upon total isotope uptake and retention in order to
deposit therapeutically relevant levels of energy in the
tumor [53]. Our in vitro 125I efflux experiments suggest
that radioiodine retention in medulloblastoma cells is
fleeting (Figure 2C), so additional measures to improve
iodide organification or slow its release may be necessary
in order to achieve clinical benefit. Certain drugs, such
as 17-(allylamino)-17-demethoxygeldanamycin and 4,4’-
diisothiocyanatostilbene-2,2’-disulfonic acid, have been
shown to increase intracellular iodide retention times in
thyroid cancer cells [16], and it is possible that they
may exert a similar effect on NIS-expressing medullo-
blastoma cells. Future studies using MV-NIS to treat
medulloblastoma should also be aimed at ascertaining
optimal viral and 131I dosing rates and expanded to
include non-invasive monitoring of viral propagation
and distribution. Our initial findings are encouraging,
however, and suggest that MV-NIS mediated radio-
virotherapy may have clinical utility in the treatment of
medulloblastoma.
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